{
  "canonical": "https://smarthernews.com/article/ceo-of-global-pharmaceutical-giant-merck-ken-frazier-speaking-about-a-potential-covid-19-treatment/",
  "ogUrl": "https://smarthernews.com/article/ceo-of-global-pharmaceutical-giant-merck-ken-frazier-speaking-about-a-potential-covid-19-treatment/",
  "ogTitle": "ceo of global pharmaceutical giant merck, ken frazier, speaking about a potential covid-19 treatment. - smarther news",
  "ogDescription": "we understand the urgency, but our goal isn’t to be the frontrunner in the early stages — it’s to develop a vaccine that is safe and effective.",
  "ogImage": "https://smarthernews.com/wp-content/uploads/2018/08/pexels-photo-415816-e1586034030296.jpeg",
  "datePublished": "2020-05-28T01:58:20+00:00",
  "dateModified": "2020-05-28T02:24:51+00:00",
  "articleSection": "quick quotes",
  "quote": "We understand the urgency, but our goal isn’t to be the frontrunner in the early stages — it’s to develop a vaccine that is safe and effective.",
  "summary": "CEO of global pharmaceutical giant Merck, Ken Frazier, speaking about a potential COVID-19 treatment.",
  "featured_image": {
    "imageUrl": "https://smarthernews.com/wp-content/uploads/2018/08/pexels-photo-415816-e1586034030296.jpeg",
    "alt": ""
  },
  "body": " <ul> <li><a href=\"https://www.merck.com/about/leadership/board-of-directors/home.html\">Frazier</a> recently did a series of interviews as the company continues to push into the competitive space for a COVID-19 treatment.</li> <li>Merck recently bought a European company working on a COVID-19 vaccine.</li> <li>Merck also partnered with a smaller U.S. company working on an antiviral treatment for COVID-19; unlike remdesevir, this treatment does not have to be administered through an IV.</li> <li><strong>Why It Matters:</strong> Frazier, although optimistic about COVID-19 pharmaceuticals, underscored the need for safety and efficiency when millions – and potentially billions – of people may eventually need the treatments developed. He said in an interview with <em>The Financial Times</em> that 12-18 months to develop a safe and effective vaccine was “very aggressive” and a timeline he did not want to commit his company too.</li> </ul> <p>Read more of his <em>Financial Times</em> interview <a href=\"https://www.ft.com/content/7b72a568-9eed-460f-b100-7bf74e3f4cbf\">HERE</a></p> ",
  "contentType": "quickquotes"
}